PAST EVENT: Antibody Engineering & Therapeutics Europe, Amsterdam, 7-9th June 2022
THIS POSITION IS NOW CLOSED.
Waving goodbye to antibody engineering and moving your lead candidates into transient protein expression is a big milestone in therapeutic antibody development. Wise developers budget a few weeks into their timelines to invest in a small-scale pilot project before scaling up.
With a quality by design approach, we employ our in silico and protein engineering expertise to design and optimize an engineering program ideal for an antibody candidate, shaped with the endpoint in mind.
World-renowned experts in the fields of antibody engineering Matthew Baker Ph.D., Professor Terry Rabbitts, and Professor Charlotte Deane to join Fusion Antibodies Scientific Advisory Panel
Fusion Antibodies has decided to include Omicron RBD, alongside the alpha, beta, gamma and delta+ RBD variants, in its development programme with the aim of producing virus-neutralising antibodies.
New $1.83 million R&D project win for Fusion Antibodies reinforces its position as one of the leading providers of early-stage antibody discovery and engineering services.
Fusion Antibodies and Eurofins Discovery sign co-marketing agreement to support timely and cost-effective development of innovative products for the benefit of global healthcare
Fusion Antibodies, pre-clinical antibody discovery and development experts and BioTickle, their exclusive distributor in India, are providing local biopharmaceutical organisations with access to invaluable unique biopharmaceutical development capabilities.
With their high specificity, efficacy and safety profiles, it’s no wonder that antibodies have become the biggest selling drugs in recent years.
info@fusionantibodies.com
+44 (0)28 9043 2800
Investor and Media
+44 (0)20 7933 8780
fusion@walbrookpr.com
Fusion Antibodies PLC, Springbank Industrial Estate, 1 Springbank Rd, Dunmurry, Belfast BT17 0QL